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It is widely believed that antibodies to the group B streptococcal (GBS) type- 
specific polysaccharides are of major importance in human host defenses against 
GBS  infection.  All  four  of the  type-specific  polysaccharides  elicit  antibodies 
against at least two forms of the antigens:  a  complete antigen  that  contains N- 
acetylneuraminic acid (sialic acid) at the nonreducing ends of the side chains and 
an incomplete or nonsialated antigen (1-4). This was first demonstrated for the 
type II  polysaccharide  by Lancefield and  Freimer  (1)  when  they showed that 
rabbit antisera directed against either the complete or incomplete antigen would 
protect mice from a lethal challenge of live type II organisms. They were unable 
to  carry  out  studies  with  type  III  GBS  using  similar  passive  protection  tests 
because these organisms were not by themselves pathogenic for mice. 
The question of antibody specificity in protection against type III GBS infec- 
tions remains controversial. There are conflicting reports regarding the protec- 
tive  properties  of human  and  rabbit  antibodies  directed  against  the  type  III 
antigens and against the capsular polysaccharide of the type 14 pneumococcus, 
which cross-reacts with the incomplete GBS type III antigen  (5). Although  it is 
possible to select for certain specificities in anti-GBS serum by specific absorptions 
with purified antigens, as was done by Lancefield and Freimer (1), the polyclonal 
nature of antisera  makes it difficult to clearly determine the immunoprotective 
effects of various specificities and different isotypes of the antibodies in question. 
Harris et al.  (6) recently reported  that  mice could be protected against  GBS 
types Ia,  Ib, Ic, or II by antibody-producing tumors formed 2 wk after subsca- 
pular injection of hybridoma cells. The protection was serotype specific. Similar 
experiments could not be carried out using type III GBS because this serotype 
was not virulent in their mouse model. 
This  report  describes  the  production  of  mouse  hybridoma  antibodies  of 
different  isotypes directed  against  both  sialated  and  nonsialated  forms  of the 
GBS  type  III  polysaccharide.  The  protective  properties  of antibodies  were 
examined under conditions where type III GBS were lethal for mice. 
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Materials and Methods 
Bacterial Strains.  Type III GBS, strain M732, was grown in Todd-Hewitt broth to log 
phase, harvested by centrifugation, and washed in PBS. Two vaccines were prepared, one 
by heat-killing at 80°C for 15 min, the other by treating with 2 N acetic acid at 80 °C for 
1 h to remove sialic acid residues. Live organisms for protection tests were suspended in 
Todd-Hewitt broth containing 15% glycerol (vol/vol), and  1-ml aliquots were frozen at 
-70°C until used. 
Hybridoma Antibodies.  BALB/c female mice were immunized intraperitoneally with 0.2 
ml of a suspension of streptococcal cells (A590  n,, -- 0.6). To obtain hybridomas against the 
complete type III antigen, heat-killed log-phase cells Were used; for hybridomas against 
the incomplete type III antigen, acid-treated cells were used. A secondary immunization 
was performed (0.1  ml intravenously and 0.2 ml intraperitoneally) 2 wk later. 4 d after 
boosting, the spleen cells were fused with Ag 8.653 cells (7) in the presence of 35% PEG 
6000 (Lot 58C 0085; Sigma Chemical Co., St. Louis, MO)and  18% dimethylsulfoxide. 
Cells were plated at a concentration of 4  x  105/well  in 24-well Linbro plates in RPMI 
1640, 20% fetal calf serum, 1 X 10  -4 M hypoxanthine, 4 x  10  -7 M aminopterin, and 1.6 
x  10 -6 M thymidine (HAT medium). 2 wk after plating, the supernates from those wells 
containing growing cells  were tested for antibody to group B type III polysaccharides 
using the enzyme-linked immunosorbent assay (ELISA) described below. Clones produc- 
ing  monoclonal antibodies  of interest  were  obtained  by  limiting  dilution  on  mouse 
peritoneal exudate feeders. Isotypes of the clones were determined by double diffusion 
in 1% agarose in phosphate-buffered saline (PBS) of the cell culture supernates (concen- 
trated 20-50-fold by (NH4)~SO4 precipitation) against isotype-specific anti-mouse immu- 
noglobulin (Litton Bionetics Inc., Kensington, MD). Larger quantities of the monoclona[ 
antibodies were obtained from the ascitic fluid of mice in which the hybridoma had been 
grown intraperitoneally. The BALB/c female mice used for this purpose were injected 
with 0.5 ml of tetramethylpentadecane (Aldrich Chemical Co., Milwaukee, WI) at least 2 
wk before the injection of hybridoma cells. 
Screening Hybridomas.  An ELISA system was used to screen hybridoma culture super- 
hates for the presence of antibody, essentially as previously described (8).  Nonsialated 
type III antigen was prepared by acid extraction and ethanol fractionation (1). Complete 
type III antigen was prepared from cells sonicated in cold 5% trichloroacetic acid and 
purified on a wheat germ agglutinin affinity column (B.  M. Gray, H. C. Dillon, Jr., and 
D. G. Pritchard, manuscript in preparation). Polystyrene autoanalyzer cups (2 ml) were 
coated  with  the  appropriate  antigen  coupled  to  poly-l.-lysine  (8).  After  washing  out 
unabsorbed antigen, hybridoma supernates (0.1  ml) were added to the cups, diluted with 
1 ml  PBS containing 0.05% Brij-35  (Aldrich Chemical Co.), and incubated for 3  h at 
room temperature. Rabbit antibody against both heavy and light chains of mouse immu- 
nogiobulins, conjugated to horseradish peroxidase (Cappel Laboratories Inc., West Ches- 
ter,  PA),  was  added  and  incubated  for  2  h.  After  washing  out  excess conjugate,  O- 
phenylenediamine/H202 substrate was added, color was allowed to develop for 30 min, 
and  was  read  at420  nm  with  a  P  1000  colorimeter (Brinkmann  Instruments,  Inc., 
Westbury, NY) (8). 
Mouse Protection Test.  Male  C3H/HeN  mice,  13-wk-old  and  ~30  g,  were obtained 
from the National Cancer Institute. The mucin model of Fleming (9,  10) was used in all 
experiments. A  10%  (wt/vol) suspension of type II hog gastric mucin (Sigma Chemical 
Co.) in  Dulbecco's balanced salt solution was prepared and autoclaved. Test mixtures 
were prepared by mixing 1 ml of the bacterial dilution, containing 1,360 colony-forming 
units (cfu) (8 x  LDg0), 1 ml of diluted (1:5) ascitic fluid or Dulbecco's balanced salt solution 
for the controls, and 2  ml of mucin. Each mouse was injected intraperitoneally with a 
total of 0.5  ml  of the  mixture.  The  LDg0 was  estimated by the  method of Reed and 
Muench (11) and corresponded to 170 cfu. 
Results 
Table  I  lists  the  hybridoma  antibodies,  their  specificity,  and  isotypes.  The 
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TABLE  I 
Hybridoma Antibodies to Type III GBS 
Clone No.*  Speci-  ficity*  Isotype  Clone No.*  Specificity* Isotype 
Fusion 1 (acid-treated cells)  Fusion 2 (log-phase  cells) 
SA19C1  III (NS)  IgM  SS15CI  III (CPL)  IgA 
SA19C3  Ill (NS)  IgM  SS15C2  llI (CPL)  IgA 
SA23C3  III (NS)  IgM  SS8C3  III (CPL)  IgG2a 
SBIC1  III (NS)  IgM  SV18C1  III (CPL)  IgM 
SB1C2  III (NS)  IgM  SV18C2  III (CPL)  IgM 
SV18C3  III (CPL)  IgM 
SB2C2  III (NS)  IgM 
SB2C3  III (NS)  IgM  SV20C1  III (CPL)  IgM 
SB3C1  III (NS)  IgM  SW8C2  III (NS)  IgG2a 
SB3C2  III (NS)  IgM  SW8C3  III (NS)  IgG2a 
SB3C3  III (NS)  IgM  SW8C4  III (NS)  IgG2a 
SD16C2  III (NS)  IgG3  SZ3C1  III (CPL)  IgM 
SE11C1  III (NS)  IgM 
SE11 C2  III (NS)  IgM 
SE11C3  III (NS)  IgM 
SZ18C1  III (CPL)  IgM 
SF2C2  III (NS)  IgM 
SF23C2  III (NS)  lgG3 
SJ9C1  III (NS)  IgM 
SJ9C2  III (NS)  IgM 
SJ9C3  lII (NS)  IgM 
* The first two letters and number of  the hybridoma code numbers designate the original hybridoma; 
C followed by a number indicates the clone. 
* NS, nonsialated; CPL, complete. 
produced monoclonal antibodies directed exclusively against the nonsialated type 
III antigen. Most of these yielded IgM antibodies, but two clones produced IgG3 
(SD 16C2 and SF23C2). The hybridoma antibodies obtained after immunization 
with whole heat-killed organisms were predominantly against the complete type 
III antigen and included clones producing IgM, IgG2a, and IgA antibodies. One 
hybridoma (SW8) from this fusion, however, produced IgG2a antibody against 
the nonsialated antigen.  The exclusive specificity of each monoclonal antibody 
for either the complete or incomplete antigen is illustrated in Fig.  1. 
Preliminary experiments indicated that the C3H/HeN strain of mice was well- 
suited for studies on the protective effect ofanti-GBS antibodies. Whereas mucin 
was required for a fatal infection, a relatively small inoculum produced consistent 
results.  It was determined that the  LDg0 for C3H/HeN  mice was  ,~ 170 cfu of 
the type III strain  M732.  Results  obtained  with  the six  monoclonal antibodies 
selected for use in the mouse protection studies are listed in Table II. Control 
mice,  which  did not  receive antibody,  were  not  protected from the  challenge 
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FIGURE  1.  Immunodiffusion reactions in 1% agarose gels between the purified type II1 GBS 
polysaccharides (0.3  mg/ml) and the monoclonal antibodies (ascitic fluids) used in the mouse 
protection tests. (A) the complete (sialated) type III polysaccharide; (B) the nonsialated type 
lII polysaccharide. The ascitic fluids in the outer well are as follows: well  1, SV18C2 (IgM); 
well 2, SE11C2 (IgM); well 3, SS8C3 (IgG2a); well 4, SW8C3 (IgG2a); well 5, SS15C2 (IgA); 
well 6, SF23C2 (IgG3). 
TABLE  II 
Protective Effect of Monoclonal Antibodies in Mice Challenged with Strain M732 
GBS 
Monoclonal anti-  No. died/No. 
body  Specificity  lsotype  t~g injected*  challenged 
SE11C2  11I (nonsialated)  lgM  ND  5/6 
SW8C3  III (nonsialated)  lgG2a  200 #g  6/6 
SF23C2  Ill (nonsialated)  IgG3  105 #g  5/6 
SV 18C2  III (complete)  lgM  198 #g  0/12 
SS8C3  llI (complete)  lgG2a  ND  0/6 
SS 15C2  Ill (complete)  IgA  60 #g  0/5 
Control*  **  --  10/10 
* The volume of antibody-containing ascitic  fluid  injected was  25  #1  per mouse; the antibody 
concentration of four ascitic fluids was determined by quantitative precipitation with the appro- 
priate antigen. ND, not determined. 
* Dulbecco's balanced salt solution was substituted for diluted ascitic fluid for the control animals. 
antigen also died, regardless of whether IgM, IgG2a, or IgG3 isotypes were used. 
Antibodies against the complete type III antigen of the IgM, IgG2a, and  IgA 
isotypes, however, were uniformly protective. All surviving mice were observed 
for at least 2 mo, and there were no additional deaths. 
Discussion 
The  mouse  hybridoma antibodies  described  in  this  study were  specific for 
either the sialated or the nonsialated form of the GBS type III polysaccharide 
antigen. Antibodies of the two different specificities did not cross-react, either 
by ELISA or by double diffusion in agarose gels, and showed marked differences 
in  functional  properties  in  the  mouse protection  studies. Jennings  et  al.  (12) 
reported  previously  that  rabbits  immunized with  GBS  type  III  produce  two 
major  populations  of antibodies,  one  specific  only  for  the  sialated  ("native") 
antigen  and  a  second  that  precipitates  both  sialated  and  nonsialated  ("core") 
antigens (12). None of our hybridoma antibodies showed this dual specificity. 
Our mouse protection model was essentially that described by Fleming (9,  10), 
using mucin to enhance the virulence of GBS type III organisms by about four 
orders  of magnitude.  Although  mucin  has  been  used  for  over  50  years  in 1010  EGAN  ET  AL.  BRIEF  DEFINITIVE  REPORT 
experimental infections in  mice (13),  the  reason  it  increases virulence is  not 
understood. Fleming showed that the ability of mucin to enhance the virulence 
of type  III  GBS  varied with different strains  of mice, suggesting that  mucin 
affected host defense mechanisms rather than the bacteria. She found that the 
virulence of GBS type III (M732) was greatly enhanced by mucin in ICR Swiss 
outbred mice while C67BL/6 inbred mice were quite resistant to infection. 
Fischer et al. (5) first noted the cross-reactivity between the nonsialated GBS 
type III antigen (made by hot acid extraction) and the pneumococcal type  14 
polysaccharide and  reported  that  antibody  to  the  pneumococcal antigen  was 
opsonic for type III GBS.  In a passive protection model using infant rats, they 
further demonstrated that  rabbit  antisera  to  pneumococcus type  14  was also 
protective in vivo against GBS type III infection (5).  Assuming that the nonsi- 
alated type III GBS antigen and the pneumococcal type 14 polysaccharides are 
structurally identical, as reported by Jennings et al.  (14),  it should follow that 
antibodies  against  the  nonsialated  GBS  type  III  antigen  should  be  similarly 
protective.  Kasper et al.  (4),  however, reported that antibodies to the sialated 
native antigen correlated best with opsonophagocytosis of type III cells and with 
protection against disease, while those against the nonsialated antigen did not. 
In our studies,  only those monoclonal antibodies directed against the sialated 
type III GBS antigen protected mice from an otherwise fatal challenge. 
There are  several  possible  explanations  for these  differences in  functional 
activity reported for the antibodies of the various specificities. Though similar 
and cross-reactive, the pneumococcal and GBS  antigens may not be precisely 
identical. The GBS type III organisms used in opsonophagocytic and protection 
tests may vary in the completeness of sialation of the exposed-type polysaccha- 
rides; the fine specificities of mouse monoclonal and rabbit polyclonal antibodies 
may differ; and  the  isotype  of the antibody  may also  play different roles  in 
protection for various animal species. 
The ability of an IgA antibody to protect against infection in our mouse model 
was quite unexpected. Using a mouse model for pneumococcus type 3 infection, 
Briles et al.  (15) found that IgA antibodies were not protective. Their model, 
however, was different in several respects, especially in the administration of a 
fairly large challenge (~ 105 organisms) by the intravenous route.  Lowell et al. 
(16) have previously demonstrated IgA-mediated phagocytosis of N.  meningititis 
by peripheral blood monocytes in an in vitro system. It is possible that in our 
model the use of a small inoculum given intraperitoneally may have permitted 
the operation of a similar mechanism involving peritoneal macrophages. This is 
currently under investigation. 
Summary 
Mouse hybridoma antibodies of several major classes against group B strepto- 
coccus type III have been produced. Mice were immunized with either whole 
heat-killed or acid-treated organisms to obtain antibodies against both the com- 
plete (sialated) or incomplete (nonsialated) forms of the type III polysaccharide. 
Resulting  monoclonal  antibodies  showed  exclusive  specificity  for  either  the 
complete or incomplete antigen. 
The ability of these antibodies to protect mice from a lethal challenge of live 
type III organisms was tested with a  mucin model that permitted use of very EGAN ET  AL.  BRIEF  DEFINITIVE  REPORT  1011 
small inocula given intraperitoneally with antibody and mucin. Antibodies spe- 
cific for the nonsialated antigen were not protective, whether of IgM, IgG2a, or 
IgG3 isotypes. Antibodies specific for the complete antigen were, however, highly 
protective, including monoclonals of IgM, IgG2a, and IgA isotypes. These mouse 
monoclonal antibodies  against  group  B  streptococci  that  are  directed  against 
either complete or incomplete antigenic determinants, and include isotypes other 
than IgM, should be particularly useful for studying the mechanism of protection 
against experimental infection. 
We thank Mrs.  Elizabeth Secor, Ms. Sheryl E. Speed, Ms. Marga Griffin-Hensley, and 
Mr. Maxwell Lynn Reeves for their expert technical assistance. 
Received  for publication 31 May 1983 and in revised  form 27June 1983. 
References 
1.  Lancefield, R. C., and E. H. Freimer. 1966. Type-specific polysaccharide antigens of 
group B streptococci. J. Hyg. 64:191. 
2.  Wilkinson, H. W.  1975.  Immunochemistry of purified polysaccharide type antigens 
of group B streptococcal types Ia, Ib, and Ic. Infect. Immun.  11:845. 
3.  Tai, J. Y.,  E. C. Gotschlich, and R. C. Lancefield. 1979.  Isolation of type-specific 
polysaccharide antigen from group B type Ib streptococci. J. Exp. Med. 149:58. 
4.  Kasper, D.  L., C. J. Baker, R. S. Baltimore, J. H. Crabb,  G. Schiffman, and H. J. 
Jennings.  1979.  Immunodeterminant specificity  of human  immunity to  type  III 
group B Streptococcus. J. Exp Med. 149:327. 
5.  Fischer, G. W., G. H. Lowell, M. H. Crumrine, andJ. W. Bass. 1978.  Demonstration 
of opsonic activity and in vivo protection against group B streptococci type III by 
Streptococcus pneumoniae type 14 antisera. J. Exp. Med. 148:776. 
6.  Harris,  M.  C.,  S.  D.  Douglas,  G.  G.  Kolski,  and  R.  A.  Polin.  1982.  Functional 
properties of anti-group B streptococcal monoclonal antibodies. Clin. Immunol. Im- 
munopathol. 24:342. 
7.  Kearney, J.  F., A. Radbruch, B. Liesegang, and K. Rajewsky.  1979.  A new mouse 
myeloma cell line that has lost immunoglobulin expression but permits the construc- 
tion of antibody-secreting hybrid cell lines. J. lmmunol.  123:1548. 
8.  Gray, B. M.  1979.  Elisa methodology for polysaccharide antigens: protein coupling 
of polysaccharides for adsorption to plastic tubes. J. Immunol. 28:187. 
9.  Fleming, D. O.  1980.  Mucin model for group B type III streptococcal infection in 
mice. Infect hnmun.  27:449. 
10.  Fleming, D. O. 1982.  Mouse protection assay for group B Streptococcus type III. Infect. 
Immun.  35:240. 
11.  Reed, J.  L., and H.  Muench.  1938.  A simple method of estimating fifty per cent 
endpoints. Am. J. Hyg. 27:493. 
12. Jennings, H. J., c. Lugowski, and D. L. Kasper. 1981. Conformational aspects critical 
to  the  immunospecificity of the  type  III  group  B  streptococcal  polysaccharide. 
Biochemistry. 20:4518. 
13.  Nungester, W. J., A. A. Wolf, and L. F. Jourdonais. 1932.  Effect of gastric mucin on 
virulence of bacteria in intraperitoneal infections in the mouse. Proc. Soc. Exp. Biol. 
Med. 30:120. 
14. Jennings, H. J., K.-G. Rosell, and D. L. Kasper. 1980.  Structural determination and 
serology of the native polysaccharide antigen of type III group B Streptococcus. Can. 
J. Biochem. 58:112. 
15.  Briles, D. E., J. L. Claflin, K. Schroer, and C. Forman. 1981. Mouse IgG3 antibodies 
are highly protective against infection with Streptococcus pneumoniae. Nature  (Lond.). 
294:88. 
16.  Lowell, G. H., L. F. Smith, J. M. Griffiss, and B. L. Brandt.  1980.  IgA-dependent, 
monocyte-mediated, antibacterial activity.J. Exp. Med. 152:452. 